Description
Description
WHO predicts that by 2020, depression will probably become the second largest disease next to cardio-cerebrovascular disease. Every year, the suicide death toll of depression around the world is up to 1 million people and the amount of depression patients in China has reached 90 million. At present, the recognition rate of depression in our country is only 30% and the identified patients seeking medical advice is also 30%, which means less than 10% of the depressive patients were likely to utilize medical service. Clinical experience shows that 80% of the patients can achieve clinical cure, if having standard treatment, expect very few patients with refractory type, others will be improvement.
Original antidepressants Fluoxetine produced by Eli Lilly and Company was approved for the treatment of depression first in Belgium in 1986.
Fluoxetine is a kind of selective serotonin reuptake inhibitors (SSRI) antidepressants and its medicinal form is Fluoxetine hydrochloride. Eli Lilly and Company named their products “the optimal solution” (Prozac) which is used for the treatment of adult depression, obsessive-compulsive disorder and neurological bulimia in clinical practice as well as panic disorder with or without agoraphobe. At the end of 1987, Fluoxetine was approved by the U.S. Food and Drug Administration (FDA) to enter American market, and it entered the Chinese market on March 30, 1995. Eli Lilly and Company’s patent for Prozac expired in August of 2001, since then there have appeared a large number of Fluoxetine drugs on the market.
There is a broad demand market of Fluoxetine in China. From 2010 to 2014, according to CRI’s survey on sample hospitals, CAGR of Fluoxetine is up to 9.68%. Eli Lilly and Company (Spain), Eli Lilly and Company (Britain), Patheon (FR), Shanghai Zhongxi Pharmaceutical Co., Ltd, Changzhou Siyao Pharmaceutical Co., Ltd, SCCPC, WATSON Pharmaceuticals (Changzhou) Co., Ltd and Shanxi C&Y Pharmaceutical Group Co., Ltd. occupy large portion in the sales market. Measured by sales value, Lilly (Spain) enjoyed the highest market share, which reached 75% in 2014.
In China, with many people bearing a proliferation of pressure from life, learning and work, the amount of depressive patients will also present an increasing tendency. In conclusion, there exists huge potential in Chinese market demand for Fluoxetine.
Table of Contents
1 Related Concepts of Fluoxetine
1.1 Indication
1.2 Sales Situation of Global Market
2 Market Profile of Fluoxetine in China
2.1 Patent and Approval Information of Fluoxetine in China
2.2 Major Manufacturers
2.3 Market Scale
3 Survey on Fluoxetine Sales Situation in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 Survey on Market Share of Major Fluoxetine Manufacturers in China, 2010-2014
4.1 Market Share of Manufacturers by Sales Value
4.2 Market Share of Manufacturers by Sales Volume
5 Survey on Dosage Forms of Fluoxetine in China, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume
6 Reference Sales Price of Fluoxetine in Chinese Hospitals in 2014
6.1 Patheon France (FR)
6.2 Shanghai Zhongxi Pharmaceutical Co., Ltd.
6.3 Shanxi C&Y Pharmaceutical Group Co., Ltd.
6.4 WATSON Pharmaceuticals (Changzhou) Co., Ltd.
6.5 Changzhou Siyao Pharmaceutical Co., Ltd.
6.6 Suzhou Chung-Hwa Pharmaceutical & Chemical Industrial Co., Ltd. (SCCPC)
6.7 Eli Lilly and Company (Britain)
6.8 Eli Lilly and Company (Spain)
7 Major Production Enterprises of Fluoxetine in Chinese Market, 2010-2014
7.1 Patheon France (FR)
7.2 Shanghai Zhongxi Pharmaceutical Co., Ltd.
7.3 Shanxi C&Y Pharmaceutical Group Co., Ltd.
7.4 WATSON Pharmaceuticals (Changzhou) Co., Ltd.
7.5 Changzhou Siyao Pharmaceutical Co., Ltd.
7.6 Suzhou Chung-Hwa Pharmaceutical & Chemical Industrial Co., Ltd. (SCCPC)
7.7 Eli Lilly and Company
8 Market Prospect of Fluoxetine in China, 2015-2019
8.1 Prediction of Market Scale
8.2 Prediction of Competition Pattern
Table of Selected Charts
Chart Patent Status of Fluoxetine in China
Chart Approval Information of Fluoxetine in China
Chart Sales Situation of Fluoxetine in China
Chart Sales Value of Fluoxetine in China, 2010-2014
Chart Sales Value of Fluoxetine in Some Regions of China, 2010-2014
Chart Sales Volume of Fluoxetine in China, 2010-2014
Chart Market Share of Corporations of TOP5 Fluoxetine Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Fluoxetine Produced by Eli Lilly and Company (Spain), 2010-2014
Chart Sales Value and Market Share of Fluoxetine Produced by Eli Lilly and Company (Britain), 2010-2014
Chart Sales Value and Market Share of Fluoxetine Produced by Patheon (FR) in China, 2010-2014
Chart Sales Value and Market Share of Fluoxetine Produced by Shanghai Zhongxi in China, 2010-2014
Chart Sales Value and Market Share of Fluoxetine Produced by Changzhou Siyao, 2010-2014
Chart Sales Value and Market Share of Fluoxetine Produced by other manufacturers in China, 2010-2014
Chart Sales Value and Market Share of Fluoxetine Tablet in China, 2010-2014
Chart Sales Value and Market Share of Fluoxetine Capsule in China, 2010-2014
Chart Sales Price of Fluoxetine Produced by Patheon France (FR) in Some Chinese Cities in 2014
Chart Sales Price of Fluoxetine Produced by Shanghai Zhongxi Pharmaceutical Co., Ltd. in Some Chinese Cities in 2014
Chart Sales Price of Fluoxetine Produced by Shanxi C&Y Pharmaceutical Group Co., Ltd. in Some Chinese Cities in 2014
Chart Sales Price of Fluoxetine Produced by WATSON Pharmaceuticals (Changzhou) Co., Ltd. in Some Chinese Cities in 2014
Chart Sales Price of Fluoxetine Produced by Changzhou Siyao Pharmaceutical Co., Ltd. in Some Chinese Cities in 2014
Chart Sales Price of Fluoxetine Produced by Suzhou Chung-Hwa Pharmaceutical & Chemical Industrial Co., Ltd. (SCCPC)in Some Chinese Cities in 2014
Chart Sales Price of Fluoxetine Produced by Eli Lilly and Company in Some Chinese Cities in 2014
